Two patient deaths during a clinical trial of Juno Therapeutics' chimeric antigen receptor therapy have prompted a halt to the initiation of treatment for new patients until changes are made to the study. The deaths were related to cytokine release syndrome. Juno Therapeutics and Memorial Sloan-Kettering Cancer Center are taking steps to prevent future deaths, and the trial could continue in several weeks pending an FDA review.

Full Story:

Related Summaries